Status:
ACTIVE_NOT_RECRUITING
Serological Autoantibodies in Early Kidney Cancer Diagnosis and Prognosis: A Multicenter Study
Lead Sponsor:
First Affiliated Hospital of Fujian Medical University
Collaborating Sponsors:
China-Japan Friendship Hospital
The First Affiliated Hospital of Xiamen University
Conditions:
Renal Carcinoma
Serology
Eligibility:
All Genders
Brief Summary
This project aims to construct a multicenter retrospective study by retrospectively collecting clinical, serological, and pathological data from patients. A comprehensive data management system will b...
Eligibility Criteria
Inclusion
- Pathological diagnosis of ccRCC;
- Availability of complete clinical, pathological, and follow-up data;
- Sufficient preoperative serum available for collection;
- Well-preserved pathological slides for subsequent immunohistochemical (chip) analysis;
- At least one post-treatment follow-up/efficacy evaluation.
Exclusion
- Therapeutic contraindication cohort: Individuals presenting with severe comorbidities rendering them medically ineligible for therapeutic interventions;
- Oncological multiplicity: Subjects with either (a) antecedent therapeutic regimens targeting non-index malignancies or (b) concurrent diagnosis of untreated active malignancies;
- Biospecimen integrity violation: Cases demonstrating serum hemolysis or compromised specimen integrity;
- Data insufficiency cohort: Patients exhibiting incomplete clinical/pathological records or insufficient longitudinal follow-up data for comprehensive analysis.
Key Trial Info
Start Date :
April 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2027
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT06917560
Start Date
April 1 2025
End Date
August 1 2027
Last Update
September 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
first hospital affiliated of Fujian medical university
Fuzhou, Fujian, China, 350005